secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYPHERPUNK TECHNOLOGIES INC. (CYPH)
CIK:        0001509745
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001104659-23-060130
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Leap Therapeutics Q1 net loss $41.9M on $29.6M IPR&D charge; cash $102M
-----------------------------------------------------------------------

- Net loss $41.9M ($10.4M Q1'22); includes $29.6M IPR&D charge from Flame acquisition.
- R&D expense $38.9M, G&A $3.8M; cash $102.0M at Mar 31, 2023.
- Completed Part A enrollment in Phase 2 DeFianCe study of DKN-01 in CRC; initial data mid-2023.
- Acquired Flame Biosciences, adding anti-Claudin18.2 candidate FL-301 and ~$50M cash.
- Will present updated long-term data from DisTinGuish study in GEA at ASCO June 5, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509745/000110465923060130/0001104659-23-060130-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509745/000110465923060130/tm2315622d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-060130

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer